Editorial illustration for TCS Unveils AI Platform as Healthcare AI Adoption Jumps to 86% in India
TCS AI Platform Revolutionizes Clinical Trial Management
TCS launches AI platform for trial oversight as India's AI use rises to 86% from 65%
Eighty-six percent. That’s the share of India's healthcare outsourcing sector now using AI, a hard leap from 65% just five years ago. Against that concrete backdrop, Tata Consultancy Services is automating the clinical trial watchdog.
The consulting giant has built a platform to monitor the studies themselves, already rolled out for over 1,300 trials across 32,000 sites. This isn't speculative tech. It is the new, operational normal for proving a drug works.
Industry trends support TCS's push toward AI-driven oversight. Adoption of AI in India's healthcare GCCs has risen sharply from 65% in 2019 to 86% in 2024, Zinnov managing partner Karthik Padmanabhan told AIM, noting that AI tools are now central to improving patient recruitment, monitoring risks, and ensuring regulatory compliance. The update comes as the life sciences industry increasingly relies on AI and analytics to navigate stricter regulations and the challenges of decentralised, adaptive trials.
TCS notes that the platform is aligned with international guidelines ICH E6(R2) and the upcoming E6(R3), and incorporates Quality by Design principles from the start of a study through execution. TCS says the platform has been used in more than 1,300 studies across 32,000 sites, a sign that AI-driven oversight is fast becoming a standard part of modern clinical research.
That 86% figure describes an operational reality, not a marketing slide. When an industry moves that fast, the tools follow. TCS is providing one, baking compliance into a trial's very design to satisfy current and looming global rules.
This is administrative infrastructure—the kind ignored until it fails. Now, algorithms check the work across tens of thousands of sites. The core aim of a clinical trial is unimpeachable data.
That process is being handed to machines that never tire of checking boxes. Trust, it seems, is being automated.
Common Questions Answered
How has AI adoption changed in India's healthcare global capability centers between 2019 and 2024?
AI adoption in India's healthcare global capability centers has dramatically increased from 65% in 2019 to 86% in 2024. This significant rise reflects the growing importance of AI tools in improving clinical trial management, patient recruitment, and regulatory compliance.
What specific capabilities does TCS's new AI platform aim to address in healthcare research?
TCS's AI platform is designed to simplify complex medical research processes, with a focus on enhancing clinical trial management. The platform targets key areas such as patient recruitment, risk monitoring, and ensuring regulatory compliance in the healthcare technology sector.
Why are AI tools becoming increasingly critical for healthcare global capability centers?
AI tools are becoming essential for healthcare global capability centers due to the need to navigate increasingly strict regulations and manage decentralized, adaptive clinical trials. These technologies help streamline complex processes, improve patient monitoring, and ensure more efficient and compliant medical research.
Further Reading
- TCS ADD™ Risk Based Quality Management Platform — TCS
- TCS ADD™: A Suite of Modern and Open Technology Platforms — TCS
- Artificial Intelligence – A Game Changer in Unifying Clinical Data — TCS
- Rewiring Clinical Research: AI-Augmented Data, Processes, and People — Applied Clinical Trials
- TCS' AI-skilled workforce doubles to 1.6 lakh; 18,500 new hires in Q2 with focus on future-ready skills — The Economic Times